SILK vs. ATRI, EMBC, KIDS, AORT, FNA, ATRC, SIBN, OFIX, IRMD, and MDXG
Should you be buying Silk Road Medical stock or one of its competitors? The main competitors of Silk Road Medical include Atrion (ATRI), Embecta (EMBC), OrthoPediatrics (KIDS), Artivion (AORT), Paragon 28 (FNA), AtriCure (ATRC), SI-BONE (SIBN), Orthofix Medical (OFIX), Iradimed (IRMD), and MiMedx Group (MDXG). These companies are all part of the "surgical & medical instruments" industry.
Atrion (NASDAQ:ATRI) and Silk Road Medical (NASDAQ:SILK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.
Atrion has higher earnings, but lower revenue than Silk Road Medical. Silk Road Medical is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.
Atrion has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, Silk Road Medical has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.
Atrion has a net margin of 10.60% compared to Atrion's net margin of -29.02%. Silk Road Medical's return on equity of 7.75% beat Atrion's return on equity.
Silk Road Medical has a consensus price target of $22.55, indicating a potential upside of 1.65%. Given Atrion's higher possible upside, analysts plainly believe Silk Road Medical is more favorable than Atrion.
In the previous week, Atrion had 3 more articles in the media than Silk Road Medical. MarketBeat recorded 5 mentions for Atrion and 2 mentions for Silk Road Medical. Atrion's average media sentiment score of 1.03 beat Silk Road Medical's score of 0.12 indicating that Silk Road Medical is being referred to more favorably in the news media.
66.2% of Atrion shares are owned by institutional investors. 22.8% of Atrion shares are owned by company insiders. Comparatively, 6.7% of Silk Road Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Atrion received 39 more outperform votes than Silk Road Medical when rated by MarketBeat users. Likewise, 55.36% of users gave Atrion an outperform vote while only 50.56% of users gave Silk Road Medical an outperform vote.
Summary
Atrion beats Silk Road Medical on 12 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding SILK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silk Road Medical Competitors List
Related Companies and Tools
